Elenoside
Latest Information Update: 14 Nov 2003
At a glance
- Originator Nonindustrial source
- Class Antineoplastics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 14 Nov 2003 Discontinued - Preclinical for Cancer in Spain (unspecified route)
- 02 Mar 1999 Preclinical development for Cancer in Spain (Unknown route)